Omar Nadeem, MD

Articles

Managing AEs Associated With Bispecifics in RRMM

Noopur Raje, MD;Jacob Laubach, MD;Omar Nadeem, MD;Andrew J. Yee, MD

July 19th 2022

Closing out their discussion on relapsed/refractory multiple myeloma, experts consider adverse event management in patients receiving bispecifics followed by future directions in care.

Bispecific Antibodies in the Treatment of RRMM

Noopur Raje, MD;Jacob Laubach, MD;Omar Nadeem, MD;Andrew J. Yee, MD

July 11th 2022

Comprehensive perspectives on the role of bispecific antibodies in the treatment of relapsed/refractory multiple myeloma.

CAR-T Therapies Therapy in RRMM

Noopur Raje, MD;Jacob Laubach, MD;Omar Nadeem, MD;Andrew J. Yee, MD

July 11th 2022

A brief review of the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Patient Profile 3: A 57-Year-Old Woman With Triple-Class Refractory MM

Noopur Raje, MD;Jacob Laubach, MD;Omar Nadeem, MD;Andrew J. Yee, MD

July 6th 2022

Moving to the last patient profile, expert panelists discuss a patient with triple-class refractory multiple myeloma managed with BCMA-targeting bispecific therapy.

Treating Transplant-Ineligible NDMM With High-Risk Cytogenetics

Noopur Raje, MD;Jacob Laubach, MD;Omar Nadeem, MD;Andrew J. Yee, MD

July 6th 2022

Shared insight on the selection of therapy for patients with transplant-ineligible, newly diagnosed multiple myeloma and high-risk cytogenetics.

Selection and Duration of Therapy in Transplant-Ineligible NDMM

Noopur Raje, MD;Jacob Laubach, MD;Omar Nadeem, MD;Andrew J. Yee, MD

June 29th 2022

Expert panelists consider which regimen they would use, and for what duration, in the setting of transplant-ineligible, newly diagnosed multiple myeloma.

Patient Profile 2: A 72-Year-Old With Transplant-Ineligible NDMM

Noopur Raje, MD;Jacob Laubach, MD;Omar Nadeem, MD;Andrew J. Yee, MD

June 29th 2022

The panel moves on to review the profile of a patient with transplant-ineligible, newly diagnosed multiple myeloma managed with dara-Rd on the MAIA trial.

Duration of Therapy in NDMM

Noopur Raje, MD;Jacob Laubach, MD;Omar Nadeem, MD;Andrew J. Yee, MD

June 22nd 2022

Before closing their discussion on transplant-eligible, newly diagnosed multiple myeloma, experts consider duration of therapy in this setting.

Selecting Appropriate Therapy for Transplant-Eligible NDMM

Noopur Raje, MD;Jacob Laubach, MD;Omar Nadeem, MD;Andrew J. Yee, MD

June 22nd 2022

Panelists briefly review factors they use to select induction therapy for patients with transplant-eligible, newly diagnosed multiple myeloma.

Quadruplet Vs Triplet Induction Regimens for Transplant-Eligible NDMM

Noopur Raje, MD;Jacob Laubach, MD;Omar Nadeem, MD;Andrew J. Yee, MD

June 15th 2022

Shared insight on approved quadruplet vs triplet induction regimens for patients with transplant-eligible, newly diagnosed multiple myeloma, evaluated in the GRIFFIN, MASTER and GMMG-HD7 trials.

Patient Profile 1: A 62-Year-Old With Transplant-Eligible NDMM

Noopur Raje, MD;Jacob Laubach, MD;Omar Nadeem, MD;Andrew J. Yee, MD

June 15th 2022

Experts discuss a patient with transplant-eligible, newly diagnosed multiple myeloma managed with induction daratumumab-RVd and maintenance therapy.